EP1589996A4 - Anti-integrin alpha beta 3 antikörper-formulierungen und ihre verwendungen - Google Patents

Anti-integrin alpha beta 3 antikörper-formulierungen und ihre verwendungen

Info

Publication number
EP1589996A4
EP1589996A4 EP04707034A EP04707034A EP1589996A4 EP 1589996 A4 EP1589996 A4 EP 1589996A4 EP 04707034 A EP04707034 A EP 04707034A EP 04707034 A EP04707034 A EP 04707034A EP 1589996 A4 EP1589996 A4 EP 1589996A4
Authority
EP
European Patent Office
Prior art keywords
antibody
integrin alpha
alpha beta
formulat ions
formulat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04707034A
Other languages
English (en)
French (fr)
Other versions
EP1589996A2 (de
Inventor
Christian B Allan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of EP1589996A2 publication Critical patent/EP1589996A2/de
Publication of EP1589996A4 publication Critical patent/EP1589996A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
EP04707034A 2003-01-30 2004-01-30 Anti-integrin alpha beta 3 antikörper-formulierungen und ihre verwendungen Withdrawn EP1589996A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44381003P 2003-01-30 2003-01-30
US44377703P 2003-01-30 2003-01-30
US443810P 2003-01-30
US443777P 2003-01-30
PCT/US2004/002701 WO2004066957A2 (en) 2003-01-30 2004-01-30 ANTI-INTEGRIN ανβ3 ANTIBODY FORMULATIONS AND USES THEREOF

Publications (2)

Publication Number Publication Date
EP1589996A2 EP1589996A2 (de) 2005-11-02
EP1589996A4 true EP1589996A4 (de) 2009-01-21

Family

ID=32829839

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04707034A Withdrawn EP1589996A4 (de) 2003-01-30 2004-01-30 Anti-integrin alpha beta 3 antikörper-formulierungen und ihre verwendungen

Country Status (5)

Country Link
EP (1) EP1589996A4 (de)
JP (1) JP2006516636A (de)
AU (1) AU2004207003A1 (de)
CA (1) CA2512174A1 (de)
WO (1) WO2004066957A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973134B2 (en) 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US20060046961A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
US7935790B2 (en) 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
JP2009503105A (ja) 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
EP1934867A2 (de) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagentien zum nachweis der proteinphosphorylierung in leukämie-signalwegen
SI2359834T1 (sl) 2006-03-15 2017-02-28 Alexion Pharmaceuticals, Inc. Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa
US7939636B2 (en) 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
AU2007293013B2 (en) 2006-09-05 2013-06-27 Alexion Pharmaceuticals, Inc. Method and compositions for the treatment of antibody mediated neuropathies
EP2094247B1 (de) 2006-10-20 2022-06-29 Amgen Inc. Stabile polypeptid-formulierungen
EP1972639A3 (de) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagenzien zur Erkennung von Proteinphosphorylierung in Karzinom-Signalwegen
US20090068684A1 (en) 2007-03-26 2009-03-12 Cell Signaling Technology, Inc. Serine and threoninephosphorylation sites
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2145902A3 (de) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
AU2008311244C1 (en) * 2007-10-09 2013-11-07 Solenis Technologies Cayman, L.P. Crosslinker-containing adhesive compositions
US20090203043A1 (en) 2007-11-21 2009-08-13 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
WO2011121560A2 (en) * 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
AU2013221635B2 (en) 2012-02-16 2017-12-07 Santarus, Inc. Anti-VLA1 (CD49a) antibody pharmaceutical compositions
MX2017005243A (es) 2014-10-23 2017-08-18 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas.
PL3464318T3 (pl) 2016-06-02 2021-11-08 Abbvie Inc. Agonista receptora glukokortykoidowego i jego immunokoniugaty
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
US10772970B2 (en) 2017-12-01 2020-09-15 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2020060183A1 (ko) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 트라스투주맙 항체 안정화 액체 제제
JP7317379B2 (ja) * 2019-01-04 2023-07-31 国立大学法人京都大学 潰瘍性大腸炎及び原発性硬化性胆管炎の検査方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010016645A1 (en) * 1997-01-30 2001-08-23 Ixsys, Incorporated Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use
WO2002013860A1 (fr) * 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees contenant un anticorps

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010016645A1 (en) * 1997-01-30 2001-08-23 Ixsys, Incorporated Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use
WO2002013860A1 (fr) * 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees contenant un anticorps
EP1314437A1 (de) * 2000-08-11 2003-05-28 Chugai Seiyaku Kabushiki Kaisha Antikörper enthaltende stabilisierte präparate

Also Published As

Publication number Publication date
CA2512174A1 (en) 2004-08-12
AU2004207003A1 (en) 2004-08-12
JP2006516636A (ja) 2006-07-06
WO2004066957A2 (en) 2004-08-12
EP1589996A2 (de) 2005-11-02
WO2004066957A3 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
EP1589996A4 (de) Anti-integrin alpha beta 3 antikörper-formulierungen und ihre verwendungen
IL174637A0 (en) Fibrosis-inducing agents, compositions containing the same and medical implants containing the same
IL173299A (en) 2,4-Pyrimidindiamine derivatives, preparations containing them and their use
EP1539941A4 (de) Adzyme und deren verwendungen
PT1736541E (pt) Nova proteína galectina 9 modificada e sua utilização
AU2003295402A8 (en) Acyl guanidine compounds and use thereof
EP1767634A4 (de) Neues galectin-8-modifikationsprotein und dessen verwendung
AU2003296369A8 (en) Imminoamines and preparation thereof
AU2003215257A8 (en) Modified defensins and their use
IL165112A0 (en) Variant integrinpolypeptides and thereof
AU2003231827A8 (en) Pseudo-tissues and uses thereof
EP1582586A4 (de) Mit apoptose assoziiertes protein und dessen verwendung
AU2003275123A8 (en) Composition containing ribavirin and use thereof
GB0227906D0 (en) Compounds and their use
EP1577322A4 (de) Neue proteine und ihre verwendung
EP1541677A4 (de) Neue proteine und verwendung davon
GB0230134D0 (en) Compounds and their use
EP1627888A4 (de) Antikörper und dessen verwendung
GB0230281D0 (en) Compounds and their use
GB0317864D0 (en) Compounds and their use
FR2859108B1 (fr) Composition anti-stress et son inhalateur
EP1699809A4 (de) Amniotisches peptid und anwendungen davon
GB2420345B (en) 3-alpha-glycosyl alpha, alpha-trehaloses their preparation and use
GB0321300D0 (en) Protein structure and uses thereof
GB0220215D0 (en) Compounds and their use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050816

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20081219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090318